VI
SUPN icon

Vestcor Inc’s Supernus Pharmaceuticals SUPN Stock Holding History

Vestcor Inc’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,405
Closed -$169K – 1292
2025
Q4 		$169K Buy
3,405
+2,000
+142% +$97.2K ﹤0.01% 990
2025
Q3 		$67K Buy
+1,405
New +$56.6K ﹤0.01% 1114
2025
Q2 		– Sell
-4,068
Closed -$133K – 1233
2025
Q1 		$133K Hold
4,068
– – ﹤0.01% 1026
2024
Q4 		$147K Hold
4,068
– – ﹤0.01% 1040
2024
Q3 		$127K Hold
4,068
– – ﹤0.01% 1031
2024
Q2 		$109K Hold
4,068
– – ﹤0.01% 1050
2024
Q1 		$139K Hold
4,068
– – ﹤0.01% 1055
2023
Q4 		$118K Hold
4,068
– – ﹤0.01% 1070
2023
Q3 		$112K Buy
4,068
+2,007
+97% +$61.1K ﹤0.01% 1102
2023
Q2 		$62K Hold
2,061
– – ﹤0.01% 952
2023
Q1 		$75K Hold
2,061
– – ﹤0.01% 1039
2022
Q4 		$74K Hold
2,061
– – ﹤0.01% 1097
2022
Q3 		$70K Buy
+2,061
New +$67.1K ﹤0.01% 1124

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vestcor Inc's SUPN Position: Q1 2026 in Review

Vestcor Inc sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 3,405 shares — an estimated $169K sold.

Vestcor Inc first reported a position in SUPN in Q3 2022 and held it in 13 quarters. The position peaked at $169K in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Vestcor Inc reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Vestcor Inc sold 3,405 Supernus Pharmaceuticals shares in Q1 2026, an estimated $169K.
  • Vestcor Inc first reported a position in Supernus Pharmaceuticals in Q3 2022 and held it in 13 quarters.
  • Vestcor Inc's Supernus Pharmaceuticals position peaked at $169K in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Vestcor Inc's 13F filing for Q1 2026, filed 12 May 2026.